People
BioSpace caught up Foghorn Therapeutics’ Steven Bellon, Ph.D., SVP, drug discovery, shortly before he chaired a panel on new epigenetic developments at the AACR Annual Meeting 2021.
Acting FDA Commissioner Janet Woodcock shared her thoughts on pandemic issues and outlined FDA modernization plans in a recent Q&A session with the Alliance for a Stronger FDA (Alliance).
Although the data is not there, Pfizer’s chief executive officer, Albert Bourla, recently said he thought people will “likely” need a booster dose of a vaccine within 12 months of getting fully vaccinated. It’s possible, he also said, they will need to be vaccinated annually.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Amarin announced the forthcoming retirement of President and CEO John Thero, and the elevation of current head of commercial for Europe and senior vice president Karim Mikhail to the top role.
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.
The biopharmaceutical industry saw two CEO appointments made today, including Howard J. Federoff, M.D., Ph.D., to Brooklyn ImmunoTherapeutics and Eric Koo to Overland ADCT BioPharma.
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
PRESS RELEASES